Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of October 2023, with specific data reported as of September 30, 2023. The document serves as a notification to the market regarding the Company's issued share capital and total voting rights in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 4,312,094,171 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 217,068,169 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,095,026,002.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data for previous reporting periods is included in this specific notification.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share capital and does not contain forward-looking statements or risk analysis.
Important Facts for Investors to Verify
- Verify the total number of voting rights (4,095,026,002) to determine if notification thresholds under FCA rules have been met.
- Confirm the number of shares held in Treasury (217,068,169) when calculating outstanding shares for ownership percentage.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.